Please input keywords
Biocytogen to Present at WAC2022, Introducing RenLite Platform and BsADC Assets

from clipboard

Biocytogen is excited to be presenting and exhibiting at the 13th Annual World ADC San Diego 2022 conference this year on September 6-9. Welcome to attend our presentation on September 6, 2022 given by our Senior Director of Antibody Therapeutics with the title of “Discovery of bispecific antibody drug conjugate (ADC) therapeutics with fully humanized RenLite common light chain transgenic mouse platform ” as well as our poster session to learn more about Biocytogen’s RenLite-based fully-human bispecific ADC platform, YH013 asset (a first-in-class EGFR x MET BsADC), and explore licensing and partnership opportunities with our BD team at booth #45!

W. Frank An, Ph.D., is the Senior Director of Antibody Therapeutics at Biocytogen. He obtained his Ph.D. in Cellular and Molecular Biology at Brandeis University, followed by postdoctoral fellowship in Immunology at Dana Farber Cancer Institute and Harvard Medical School. He has over twenty years’ experience working in drug discovery in both industry and academia settings.